ARTICLE
3 May 2023

U.S. Supreme Court Declines To Review Decision Blocking Prop. 65 Acrylamide Cancer Lawsuits

GG
Greenberg Glusker Fields Claman & Machtinger

Contributor

Greenberg Glusker is a full-service law firm in Los Angeles, California with clients that span the globe. For 65 years, the firm has delivered first-tier legal services, rooted in understanding clients' intricate business needs and personal concerns. With tailored solutions driving outstanding results, we go beyond the practice of law; we become committed partners in our clients' success.
For those following the acrylamide saga (see, e.g., our earlier blog post), on Monday of this week, the U.S. Supreme Courtdeclined to review the injunction blocking new Prop. 65 lawsuits...
United States California Finance and Banking

For those following the acrylamide saga (see, e.g., our earlier blog post), on Monday of this week, the U.S. Supreme Courtdeclined to review the injunction blocking new Prop. 65 lawsuits as to cancer warning labels on foods containing acrylamide:

1311036a.jpg

By way of background, Prop. 65 requires businesses to warn Californians about exposures to chemicals known to the State of California to allegedly cause cancer, birth defects, or other reproductive harm. The Prop. 65 list of chemicals presently includes around 1,000 chemicals, including acrylamide, a substance that forms when certain foods (like bread, coffee, and French fries) are cooked at high temperatures.

Following a proliferation of lawsuits based on acrylamide cancer risk, in March 2021, U.S. District Judge Kimberly J. Mueller issued a preliminary injunction barring such lawsuits given the unclear science regarding whether acrylamide in food actually causes cancer in humans. In other words, the State had not shown that required acrylamide cancer warnings were "purely factual and uncontroversial."

In May 2021, a three-judge panel of the Ninth Circuit granted an emergency stay of the District Court's preliminary injunction, finding that the intervenor (CERT) was likely to prevail on appeal and raising concerns that the injunction violated the prior restraint doctrine, among other matters.

In March 2022, however, a three-judge panel of the Ninth Circuit affirmed the District court's grant of the preliminary junction finding that, among other things, the scope of the injunction was not impermissible and that the injunction would be in the public interest. In October 2022, the Ninth Circuit declined to review the preliminary injunction en banc.

The Supreme Court's denial of certiorari on Monday means that Hon. Mueller's preliminary injunction will stand for the foreseeable future. In other words, acrylamide lawsuits based on cancer risk remain blocked.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More